Aristides Capital’s Gilead Sciences GILD Stock Holding History

Aristides Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-18,300	Closed	-$1.37M	–	129
2020 Q1	$1.37M	Buy	+18,300	New	+$1.26M	0.99%	19

Other funds holding GILD

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Aristides Capital's GILD Position: Q2 2020 in Review

Aristides Capital sold out of Gilead Sciences (GILD) in Q2 2020, closing a stake of 18,300 shares — an estimated $1.37M sold.

Aristides Capital first reported a position in GILD in Q1 2020 and held it in 1 quarter. The position peaked at $1.37M in Q1 2020. 1,625 funds tracked by Wall St. Rank hold GILD as of Q2 2020.

Aristides Capital reported no remaining Gilead Sciences position as of Q2 2020 after selling out during the quarter.
Aristides Capital sold 18,300 Gilead Sciences shares in Q2 2020, an estimated $1.37M.
Aristides Capital first reported a position in Gilead Sciences in Q1 2020 and held it in 1 quarter.
Aristides Capital's Gilead Sciences position peaked at $1.37M in Q1 2020.
1,625 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2020.

Based on Aristides Capital's 13F filing for Q2 2020, filed 14 Aug 2020.